The CBX5 Knockout HeLa Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the CBX5 gene has been disrupted, generating a heterogeneous pool of HeLa cells with loss-of-function mutations at the target locus. This polyclonal format preserves the diversity of editing outcomes and is well suited for studying gene function without the bias of single-cell cloning. The knockout model enables investigation of CBX5-dependent chromatin regulation and its impact on cancer cell behavior in a well-established human epithelial cell background.
HeLa cells, derived from a cervical adenocarcinoma, are HPV18-positive and immortalized, exhibiting robust proliferation and widespread use in biomedical research including cancer biology, virology, and epigenetics. Their epithelial morphology and genetic tractability make them a versatile host for CRISPR-mediated gene disruption. The HeLa background offers a relevant context for examining how CBX5 loss influences heterochromatin organization and gene expression programs in a cancer cell line, particularly for cervical cancer and other HPV-associated malignancies.
CBX5 (HP1??) functions as a key component of pericentric and telomeric heterochromatin by binding methylated histone H3 at lysine 9 (H3K9me2/me3) through its chromodomain, thereby promoting chromatin compaction and transcriptional repression. It is recruited by H3K9 methyltransferases SUV39H1 and SUV39H2 and forms complexes with other HP1 family members CBX1 (HP1??) and CBX3 (HP1??), as well as with Lamin B receptor, DNMT1, CAF-1, and TIF1??. CBX5 activity is regulated upstream by E2F transcription factors, the RB protein, p53, CK2 kinase, Aurora B kinase, Plk1 kinase, SUMO1, and DNA damage sensors. Downstream, CBX5-dependent silencing influences expression of p21/CDKN1A, p16/CDKN2A, BAX, cyclin genes, and indirectly E-cadherin, linking heterochromatin maintenance to cell cycle control, apoptosis, and differentiation.
In the HeLa context, CBX5 knockout is expected to alleviate heterochromatin-mediated gene silencing, leading to derepression of loci involved in tumor suppression, cell cycle arrest, and DNA damage responses. This may alter proliferation rates, sensitize cells to genotoxic stress, and modify responses to epigenetic therapies such as HDAC inhibitors. By disrupting the H3K9me3?CHP1?? interaction, the model provides a platform to interrogate the role of heterochromatin in cancer cell survival, genome stability, and therapeutic resistance, with direct relevance to cervical cancer and other epithelial tumors where epigenetic dysregulation is a hallmark.
This polyclonal knockout cell pool is suitable for a range of downstream assays including Western blotting for H3K9me3 and CBX5, RT-qPCR to measure reactivation of silenced genes, transcriptome-wide RNA-seq, ChIP-qPCR for H3K9me3 enrichment, immunofluorescence to visualize heterochromatin foci, colony formation assays, Annexin V apoptosis assays, flow cytometry-based cell cycle analysis, Comet assays for DNA damage, and drug sensitivity screens with HDAC inhibitors. These applications support research in chromatin biology, epigenetic regulation of gene expression, cancer cell biology, and preclinical drug screening. For further information, please contact Ascent Research.
